TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01761656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: loading dose atorvastatin
Description: For loading dose atorvastatin intervention, patients will be treated with 80 mg atorvastatin (lipitor) 12 hours before PCI and 40 mg atorvastatin (lipitor) 2 hours before PCI and then 20mg/d after PCI.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: conventional dose atorvastatin
Description: For conventional dose atorvastatin intervention, patients will be treated with 20 mg atorvastatin (lipitor) 12 hours before PCI and then 20mg/d after PCI.
Study: NCT00206947

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: donepezil (5-10 mg/day)
Description: Donepezil will be administered in a dose optimized for treatment, to patients who are stabilized on a ziprasidone treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be added to the medication of schizophrenia patients who are first stabilized on a ziprasidone treatment
Study: NCT04542135

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulindac Pill
Description: Randomized participants will receive either 150 mg oral sulindac twice daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo pills twice daily
Study: NCT01627054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT7519M
Description: Dose: 27 mg/m2, IV injection, 1 hour infusion Schedule: 27 mg/m2/day twice weekly x 2 weeks every 3 weeks (days 1, 4, 8 and 11)
Study: NCT00927433

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention for cancer-related fatigue
Description: Patients received education on fatigue management in groups of ten patients over two weeks in three two hour sessions

Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: Psychoeducational intervention for cancer-related fatigue
Description: Patients received education on fatigue management in groups of ten patients over two weeks in three two hour sessions
Study: NCT02036502

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous (IV) infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous (IV) infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous (IV) infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous (IV) infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous (IV) infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous (IV) infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous (IV) infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Oral tablet IV infusion
Study: NCT06140459

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pulsating Toothbrushes
Description: Oral-B Pulsar, Colgate 360º Micro Sonic Power
Study: NCT01306656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10,000 IU Vitamin D3
Description: Month 1: 20,000 IU vitamin D3 once a week~Months 2-6: 10,000 IU vitamin D3 once a week

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Month 1: Placebo once a week~Months 2-6: Placebo once a week

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Daily multivitamin with 400 IU vitamin D.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D
Description: Daily multivitamin with 400 IU vitamin D.
Study: NCT01570049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: for injection
Study: NCT03344627

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meropenem standard dose
Description: * Empirical with 1 g meropenem intravenous infusion in 30 minutes then 1 g intravenous infusion in 3 hours every 8 hours.~* Dosage is adjusted in case of renal dysfunction. Duration of therapy is varied regarding source(s) of infection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meropenem high dose
Description: * Empirical with 2 g meropenem intravenous infusion in 30 minutes then 2 g intravenous infusion in 3 hours every 8 hours.~* Dosage is adjusted in case of renal dysfunction. Duration of therapy is varied regarding source(s) of infection
Study: NCT01321957

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin, 5FU/LV, Bevacizumab
Description: bevacizumab at a dose of 5 mg/kg iv over 30 to 90 min (day 1) oxaliplatin at a dose of 85 mg/m2 iv over two hours (day 1) I-LV at a dose of 200 mg/m2 iv over two hours (day 1) 5-FU at a dose of 3200 mg/ m2 iv over 48 hours (day 1-3)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5FU/LV, Oxaliplatin, Bevacizumab, Irinotecan
Description: bevacizumab at a dose of 5 mg/kg iv over 30 to 90 min (day 1) irinotecan at a dose of 165 mg/m2 iv over two hours (day 1) oxaliplatin at a dose of 85 mg/m2 iv over two hours (day 1) I-LV at a dose of 200 mg/m2 iv over two hours (day 1) 5-FU at a dose of 3200 mg/ m2 iv over 48 hours (day 1-3)
Study: NCT02036502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Oral tablet IV infusion
Study: NCT03046225

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation
Description: TENS was applied in the conventional mode, through two self-adhesive electrodes of size 5x9cm positioned parallel to the lumbar spine, on the nerve roots of L3, L4 and L5, with frequency of 100 Hz and pulse duration of 100 μs, for 30 minutes. The intensity was adjusted according to the maximum tolerance of the patient and was gradually increased, with his permission, during the application time.
Study: NCT02036502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Oral tablet IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Oral tablet IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Oral tablet IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Oral tablet IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Oral tablet IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Oral tablet IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: IV infusion
Study: NCT02608554

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Taichi
Description: The program of Taichi training consisted of 60 minutes exercise sessions, 3 days per week for 12 weeks, based on their original level of physical activity. Each session comprised 40 minutes of Taichi training plus a 10-minute warm-up and cool-down. The Taichi training was instructed by the same experienced Taichi instructors who were qualified in the teaching of Taichi. The 24 forms of simplified Taichi recommended as the popular health sport by the General Administration of Sport of China were applied.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-monitored exercise
Description: Exercise was self-monitored and consisted of brisk walking, cycling, jogging, or any other aerobic exercise for 60 mins. 3 days per week for 12 weeks.
Study: NCT03021850

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Flexibility training with or without different thermal modalities
Description: Flexibility training of the hamstring muscles by passive static stretching of the hamstring muscles in 10 30-second repetitions, with a 10-second pause between each repetition associated with or without short-wave heating or cryotherapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Flexibility training with or without different thermal modalities
Description: Flexibility training of the hamstring muscles by passive static stretching of the hamstring muscles in 10 30-second repetitions, with a 10-second pause between each repetition associated with or without short-wave heating or cryotherapy
Study: NCT04022876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed administered IV on Day 1 of every 21-day cycle.
Study: NCT03021850

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Flexibility training with or without different thermal modalities
Description: Flexibility training of the hamstring muscles by passive static stretching of the hamstring muscles in 10 30-second repetitions, with a 10-second pause between each repetition associated with or without short-wave heating or cryotherapy
Study: NCT04416087

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Positron emission tomography (PET) imaging at rest and during supine bicycle exercise Tumor blood flow and its heterogeneity will be measured with PET at rest and during supine bicycle exercise.
Study: NCT01821534

Intervention type: OTHER
Intervention: No Intervention
Description: No treatment (intervention) was administered.
Study: NCT02101047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Study: NCT03968302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARM A Triple therapy for helicobacter pylori
Description: The triple regimen was defined as a combination of amoxicillin 1 gm twice a day, clarithromycin 500 mg twice a day and omeprazole is given in 40 mg twice a day dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARM B Quadruple therapy for helicobacter pylori
Description: Quadruple therapy included colloidal bismuth subcitrate 240 mg twice daily,amoxicillin 1 gm twice a day, clarithromycin 500 mg twice a day and omeprazole is given in 40 mg twice a day dose.
Study: NCT02786628

Intervention type: OTHER
Intervention: Physical performance testing and patient-generated health data
Description: All patients will complete cardiopulmonary exercise testing and 6 minute walk distance performance testing prior to a cycle of chemotherapy (or transplant) and wear a Fitbit Charge HR for the duration of one cycle of chemotherapy.

Intervention type: OTHER
Intervention: Physical performance testing and patient-generated health data
Description: All patients will complete cardiopulmonary exercise testing and 6 minute walk distance performance testing prior to a cycle of chemotherapy (or transplant) and wear a Fitbit Charge HR for the duration of one cycle of chemotherapy.
Study: NCT00753259

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Care as Usual
Description: Routine clinical care of atrial fibrillation patients, provided by cardiologists, without the help of specialized nurses or dedicated software.
Study: NCT02791295

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet and physical activity program
Description: A personalized intervention focused on improving diet and increasing physical activity will be implemented at-home with a monthly support by a registered dietician and physical activity educator during 6 months
Study: NCT02786628

Intervention type: OTHER
Intervention: Physical performance testing and patient-generated health data
Description: All patients will complete cardiopulmonary exercise testing and 6 minute walk distance performance testing prior to a cycle of chemotherapy (or transplant) and wear a Fitbit Charge HR for the duration of one cycle of chemotherapy.
Study: NCT03046225

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous passive movement device
Description: CPM device was used for 30 minutes and realized continuous passive flexion and extension of the operated knee.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous passive movement device
Description: CPM device was used for 30 minutes and realized continuous passive flexion and extension of the operated knee.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercises
Description: Active exercises of plantar flexion and dorsal flexion of the ankles, adduction and abduction of the hips and flexion and extension of the operated knees. All exercises were performed in 10 repetitions, with the patient positioned in the supine position in the bed.
Study: NCT04474860

Intervention type: DIAGNOSTIC_TEST
Intervention: gene sequencing
Description: Gene fragment analysis, Sanger sequencing method and/or high-throughput whole-genome sequencing will be performed to find the pathogenic gene and mutation site of MH in Chinese population.
Study: NCT03852550

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: e-health application
Description: In the first part of this study, an e-health application (MyREADY Transition\[TM\] BBD App) was developed, targeting the needs of youth with BBD during their transition and transfer from pediatric to adult health care. Program development centered on three core foci of health care transition planning: education, empowerment, and navigation. The intervention has an emphasis on the process of transition in which youth and young adults learn information and develop skills in order to eventually assume maximal responsibility for self-management of their conditions (e.g., learning how to speak directly with health providers) while also providing information to prepare youth for the event of the transfer from pediatric to adult health care.
Study: NCT01568931

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Urokinase
Description: intracoronary, urokinase, 200,000 Units, bolus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: intracoronary, saline, bolus 1 cc
Study: NCT00625976

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Graded exposure in vivo
Description: Graded exposure in vivo according to the protocol of de Jong et al. (2005)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: Physiotherapy according to the protocol of Oerlemans, Oostendorp, de Boo and Goris (1999)
Study: NCT03558243

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Patent Hemostasis arm
Description: Patent hemostasis with TR BAND

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ULTRA arm
Description: Patent hemostasis protocol plus ipsilateral ulnar compression

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemostatic disc arm
Description: StatSeal disc plus TR Band
Study: NCT02306629

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Epratuzumab sc
Description: Active substance: Epratuzumab, Pharmaceutical form: Solution for injection, Route of Administration: Subcutaneous,

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Epratuzumab sc
Description: Active substance: Epratuzumab, Pharmaceutical form: Solution for injection, Route of Administration: Subcutaneous,

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Epratuzumab sc
Description: Active substance: Epratuzumab, Pharmaceutical form: Solution for injection, Route of Administration: Subcutaneous,

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Epratuzumab iv
Description: Active substance: Epratuzumab, Pharmaceutical form: Solution for Infusion, Route of Administration: Intravenous,
Study: NCT01907672

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rapid Diagnostic Test
Description: Rapid Diagnostic Test for Malaria carried out to direct antimalarial dispensing. No antimalarials for negative tests, antimalarials for positive tests
Study: NCT04351087

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Platelet Rich Plasma
Description: Platelet rich plasma: 157cc of whole blood will be collected, processed, and injected into the knee joint under sterile technique using ultrasound-guidance.~Microfragmented adipose tissue: Adipose will be aspirated from the subcutaneous tissue of the buttock or abdomen, processed, and injected into the knee joint under sterile technique using ultrasound-guidance.
Study: NCT04022876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed administered IV on Day 1 of every 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo administered IV on Days 0-2 prior to carboplatin and pemetrexed administered IV on Day 1 of every 21-day cycle.
Study: NCT04251988

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oculus Go VR
Description: virtual reality headset
Study: NCT01120457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-936564 (Anti-CXCR4)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-936564 (Anti-CXCR4)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-936564 (Anti-CXCR4)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-936564 (Anti-CXCR4)
Study: NCT03046225

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercises
Description: Active exercises of plantar flexion and dorsal flexion of the ankles, adduction and abduction of the hips and flexion and extension of the operated knees. All exercises were performed in 10 repetitions, with the patient positioned in the supine position in the bed.
Study: NCT03163082

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Intervention
Description: The cognitive intervention has partners come up with reasons why their partners do things they don't like, until they come up with benign attributions for those behaviors.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Intervention
Description: The behavioral intervention has partners develop an if-then plan for dealing with conflict and negativity, using strategies to downregulate their own negative emotions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interpretation Bias
Description: The Interpretation Bias intervention has partners look at morphed facial expressions and determine whether the face is happy or angry. Positive feedback is given for rating the faces as happy and negative feedback is given for rating the faces as angry.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Evaluative Conditioning
Description: The Evaluative Conditioning intervention presents partners with pictures of ambiguous adult faces (conditioned stimuli) and pairs them with positive word descriptors (unconditioned stimuli; e.g., generous; loving).
Study: NCT03603444

Intervention type: OTHER
Intervention: No intervention are provided

Intervention type: OTHER
Intervention: No intervention are provided

Intervention type: OTHER
Intervention: No intervention are provided
Study: NCT01591876

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intradialytic aerobic exercise
Description: Participants in the intervention group will undertake moderate intensity aerobic exercise. Exercise modality will be recumbent cycling during the first two hours of haemodialysis sessions. Exercise prescription is set using a graded exercise test and anchored to a perceived level of exertion using the BORG scale. Training stimulus is maintained by the participant by increasing the cycling resistance when perceived exertion drops by one point at the current resistance level. Adherence and training volume is recorded during the intervention period.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Progressive Muscle relaxation
Description: This is a sequence of stretching and relaxation of the major muscle groups of the body. Participants are initially given detailed information regarding the technique and then provided with a recorded version which they listen to for 30-40 minutes during dialysis sessions. Participants in this group are offered the exercise programme at the end of three months.
Study: NCT02556333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTC/TAF
Description: Tenofovir alafenamide (TAF) is an investigational oral prodrug of tenofovir. This trial will explore the safety and efficacy of TAF in a fixed combination with emtricitabine (FTC) (F/TAF, Gilead Sciences Inc.) as part of a salvage antiretroviral regimen for HIV-1-infected adults and adolescents (greater than or equal to 14 years) who experienced virologic failure.
Study: NCT00056563

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral Deep Brain Stimulation
Description: The DBS site (STN or GPi) will be assigned on a random basis at the time the patient enters the surgical phase of the trial.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: best medical therapy
Description: Participants will initially be randomized to DBS or to 6 months of best medical therapy. BMT participants will then proceed into the surgical phase of the trial. Effective 08/05/05, randomization to the BMT arm has been discontinued since the study has sufficient information to compare the outcomes of DBS and BMT patients at 6 months.
Study: NCT01632969

Intervention type: BEHAVIORAL
Intervention: The The Family Assessment of Treatment at the End of life (FATE ) survey
Description: Study candidates will be contacted by mail with an initial contact letter with information explaining the study, and then will receive a follow-up phone call to discuss their participation in the study no later than 1 month following the posting of the initial contact letter. If a family member or next-of-kin chooses to participate, verbal informed consent will be obtained over the phone and a one-time telephone interview will be conducted.
Study: NCT03444922

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ingestion of Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BPA 4 ug/kg BW
Description: Oral BPA ingestion of 4 ug/kg BW

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BPA 50 ug/kg BW
Description: Oral BPA ingestion of 50 ug/kg BW
Study: NCT02401880

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linagliptin
Description: 22 subjects will receive Linagliptin for 30 days
Study: NCT01274507

Intervention type: OTHER
Group type: OTHER
Intervention: Medical tests
Description: All participants will undergo medical tests and will be observed.